A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

* Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile * Subjects must meet one of the following: * Treatment-naive: Subject has never received antiviral treatment for hepatitis C infection OR * Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegIFN/RBV); * Body mass index (BMI) is ≥ 18 to \< 38 kg/m\^2. * Chronic HCV genotype 1b infection/with or without cirrhosis or HCV genotype 4 infection/without cirrhosis for at least 6 months prior to study screening. * Subject has plasma HCV RNA level \> 10,000 IU/mL at Screening

* History of severe, life-threatening or other significant sensitivity to any drug. * Females who were pregnant or planned to become pregnant, or breastfeeding, or GT4-infected males whose partners were pregnant or planning to become pregnant within 7 months (or per local RBV label) after their last dose of study drug/RBV. * Recent history of drug or alcohol abuse that could preclude adherence to the protocol. * Positive test result for hepatitis B surface antigen or anti-Human Immunodeficiency Virus (HIV) antibodies.